期刊文献+

血管紧张素转换酶抑制剂对阻塞性睡眠呼吸暂停低通气综合征合并高血压患者睡眠呼吸障碍干预效应的研究 被引量:1

Effects of angiotensin converting enzyme inhibitors on apnea and hypopnea in patients with obstructive sleep apnea-hypopnea syndrome complicated by hypertension
原文传递
导出
摘要 目的 研究血管紧张素转换酶抑制剂(ACEI)对于阻塞性睡眠呼吸暂停低通气综合征(OSAHS)合并高血压患者睡眠呼吸障碍的干预效应.方法 63例经多导睡眠图证实的OSAHS患者被纳入本研究(男54例,女9例),平均年龄(53±12)岁,按照其病情和服药情况分为3组,OSAHS无高血压组(A组)21例,OSAHS合并高血压未服降压药组(B组)19例,OSAHS合并高血压服用ACEI类降压药组(C组)23例.比较三组患者睡眠呼吸暂停低通气指数(AHI),睡眠时最低血氧饱和度(LSaO2).结果 C组患者AHI明显低于B组[(21,32±3.53)次/h vs(38.99±2.51)次/h,P<0.05],LSaO2明显高于B组[(79.43士7.54)%vs(72.56±10.5)%,P<0.05];C组和A组AHI和LSaO2差异无统计学意义(P>0.05).结论 ACEI类降压药可能具有改善OSAHS合并高血压患者睡眠呼吸障碍的效应. Objective To investigate the effects of angiotensin converting enzyme inhibitors (ACEI) on apnea and hypopnea in patients with obstructive sleep apnea-hypopnea syndrome(OSAHS)complicated by hypertension. Methods 63 subjects with OSAHS examined by polysomnography (PSG)were enrolled in this study (male 54, female 9), average age ( 53 ± 12 ) years. The subjects were divided into 3 groups, group A(pure OSAHS group, n = 21), group B(hypertension patients with OSAHS without antihypertensive treatment group, n = 19), group C(hypertension patients with OSAHS with ACEI group, n =23). All subjects underwent 8-hour PSG monitoring and their data were analyzed. The apnea-hypopnea index (AHI) and lowest SaO2 (LSaO2) were compared among the three groups. Results The AHI of group C were lower significantly than that of group B [(21. 32±3. 53) n/h vs (38. 99±2.51) n/h,P 〈0. 05], while LSaO2 of group C were higher significantly than that of group B [(79. 43±7. 54) % vs(72.56±10. 5) %, P 〈0.05]. There was no significant difference in AHI and LSaO2 between group A and group C. Conclusions ACEI may have improving effects on apnea and hypopnea in hypertension patients with OSAHS.
出处 《国际呼吸杂志》 2011年第7期503-506,共4页 International Journal of Respiration
关键词 阻塞性睡眠呼吸暂停低通气综合征 血管紧张素转换酶抑制剂 呼吸暂停 低通气 Obstructive sleep apnea-hypopnea syndrome Angiotensin converting enzyme inhibitors Apnea Hypopnea
  • 相关文献

参考文献15

  • 1Kimoff RJ. Upperairway myopathy is important in the pathophysiology of obstructive sleep apnea. J Clin Sleep Med,2007,3.-567 569.
  • 2Dunleavy M, Bradford A, O'Halloran KD. Oxidative stress impairs upper airway muscle endurance in an animal model of sleep disordered breathing. Adv Exp Med Biol. 2008, 605: t58 462.
  • 3孙兴华,张立强,贺蓓,李枫,唐岩,王建东.牛磺酸对代谢综合征大鼠胸骨舌骨肌结构与功能的影响[J].中华医学杂志,2008,88(19):1363-1366. 被引量:2
  • 41.iu Y. Wang I., 1.i X, et al. Tanshinone I1A improves impaired nerve functions in experimental diabetic rats. Biochem Biophys Res Commun,2010,399:49-54.
  • 5Liang W, Tan CY, Ang L, et al. Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice. J Physiol Sci,2008,58~405-411.
  • 6Veresh Z, Racz A, Lotz G, et al. ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD (P) H oxidase pathway. Hypertension, 2008,52 = 960-966.
  • 7Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, et al. Novel approaches to improving endothelium dependent nitric oxide-mediated vasodilatation. Pharmacol Rep, 2009, 61 : 10,5-115.
  • 8Minami N, Li Y, Guo Q, et converting enzyme inhibitor and capacity and ~keletal mu:~cle 1Z41-1248. al. Effects of angiotensin- exercise training on exercise Hypertension, 2007, 25:.
  • 9Coppey LJ, Davids0n EP, Rinehart TW,et al. ACE inhibitor or angiotensln II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes, 2006,55 : 341-348.
  • 10Cofta S, Wysocka E, Piorunek T, et al. Oxidative stress markers in the blood of persons with different stages ofobstructive sleep apnea syndrome. J Physiol Pharmacol, 2008,59 (Suppl 6) :183-190.

二级参考文献12

  • 1Wiernsperger N, Nivoit P, Bouskela E. Obstructive sleep apnea and insulin resistance: a role for microcirculation? Clinics, 2006, 61:253-266.
  • 2Vgontzas AN, Birder EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev, 2005, 9:211-224.
  • 3Frisbee JC. Impaired skeletal muscle perfusion in obese Zucker rots. Am J Physiol Regul Integr Comp Physiol, 2003, 285: R1124-R1134.
  • 4Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol, 2005, 289:R307-R316.
  • 5Chapman MJ. Metabolic syndrome and type 2 diabetes : lipid and physiological consequences. Diab Vasc Dis Res, 2007,4 ( Suppl 3) :S5-S8.
  • 6Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab,2006, 8 : 136-145.
  • 7Frisbee JC, Delp MD. Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion:lessens from the obese Zucker rat. Essays Biochem, 2006, 42:145-161.
  • 8Askew CD, Green S, Walker PJ, et al. Skeletal muscle phenotype is associated with exercise tolerance in patients with peripheral arterial disease. J Vase Surg,2005,41:802-807.
  • 9Tas S, Sarandol E, Ayvalik SZ, et al. Vanadyl sulfate, taurine, and combined vanadyl sulfate and taurine treatments in diabetic mrs : Effects on the oxidative and antioxidative systems. Arch Med Res, 2007,38 : 276 -283.
  • 10Edwards JN, Macdonald WA, van der Poel C, et al. 02(*-) production at 37 degrees C plays a critical role in depressing tetanic force of isolated rat and mouse skeletal muscle. Am J Physiol Cell Physiol, 2007, 293:C650-C660.

共引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部